drugset / Trial / NCT00124891

Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia

NCT00124891 ↗

Phase 2 Terminated 500 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupDouble-blindPrevention

Summary

To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).

Timeline

Start
2005-06-01
Primary completion
2006-11-01
Completion
2006-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GAP-486 Unknown — —